Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate
  • Synaptogenix Inc SNPX stock is plunging on heavy volume in reaction to the release of additional analyses of its Alzheimer's candidate bryostatin, showing that it missed primary endpoints.
  • The analyses were based on the results of two clinical studies.
  • Data were presented at the Alzheimer's Association International Conference (AAIC). An abstract of the analyses showed that one study suffered from baseline imbalance.
  • Another study was impacted by AbbVie Inc's ABBV Namenda (memantine) blocking bryostatin efficacy, according to Synaptogenix.
  • However, the pooled analyses showed that the two studies produced a highly significant statistical separation of the bryostatin group from the placebo group.
  • Price Action: SNPX shares are down 19.6% at $9.73 during the market session on the last check Monday.

Posted In: Alzheimer's diseaseBriefsBiotechNewsShort IdeasHealth CareMoversTrading IdeasGeneral